

# CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

View Online



1

Weinberg RA. The biology of cancer. 2nd ed. New York: : Garland Science 2014.

2

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;**100**:57-70.  
doi:10.1016/S0092-8674(00)81683-9

3

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;**144**  
:646-74. doi:10.1016/j.cell.2011.02.013

4

Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC  
Biology 2010;**8**. doi:10.1186/1741-7007-8-38

5

Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer Genome Landscapes. Science  
2013;**339**:1546-58. doi:10.1126/science.1235122

6

Lee TI, Young RA. Transcriptional Regulation and Its Misregulation in Disease. Cell 2013;  
**152**:1237-51. doi:10.1016/j.cell.2013.02.014

7

Children's cancer statistics | Cancer Research UK.  
<http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>

8

International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. Revised 4th edition. Lyon: : International Agency for Research on Cancer 2016.

9

Taylor, Michael D Northcott, Paul A Korshunov, Andrey Remke, Marc Cho, Yoon-jae. Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica*; **123**:465–72. [https://search.proquest.com/docview/928783888?rfr\\_id=info%3Axri%2Fsid%3Aprim](https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprim)

10

Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. *Nature* 2010; **468**:1095–9. doi:10.1038/nature09587

11

Ellison DW, Onilude OE, Lindsey JC, et al.  $\beta$ -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. *Journal of Clinical Oncology* 2005; **23**:7951–7. doi:10.1200/JCO.2005.01.5479

12

Nataliya Zhukova. Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. *Journal of Clinical Oncology* 2013; **31**. doi:10.1200/JCO.2012.48.5052

13

Stone TJ, Jacques TS. Medulloblastoma: selecting children for reduced treatment. *Neuropathology and Applied Neurobiology* 2015;**41**:106–8. doi:10.1111/nan.12193

14

Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. *The Lancet Oncology* 2017;**18**:958–71. doi:10.1016/S1470-2045(17)30243-7

15

Pfister S, Remke M, Castoldi M, et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica* 2009;**117**:457–64. doi:10.1007/s00401-008-0467-y

16

Korshunov, Andrey Sturm, Dominik Ryzhova, Marina Hovestadt, Volker Gessi, Marco. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*; **128**:279–89. <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&accountid=14511>

17

Schwalbe EdC, Hayden JT, Rogers HA, et al. Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. *Acta Neuropathologica* 2013;**126**:943–6. doi:10.1007/s00401-013-1206-6

18

Sturm D, Orr BA, Toprak UH, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell* 2016;**164**:1060–72. doi:10.1016/j.cell.2016.01.015

19

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola. Autopsy in children with

cancer who die while in terminal care. *Medical and Pediatric Oncology* 1998;**30**:284–9. doi:10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B

20

Buckner T, Blatt J, Smith SV. The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience. *Pediatric and Developmental Pathology* 2006;**9**:374–80. doi:10.2350/06-02-0047.1

21

Bleggi-Torres LF, de Noronha L, Schneider Gugelmin E, et al. Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system. *Diagnostic Cytopathology* 2001;**24**:293–5. doi:10.1002/dc.1062

22

Hill RM, Kuijper S, Lindsey JC, et al. Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. *Cancer Cell* 2015;**27**:72–84. doi:10.1016/j.ccell.2014.11.002

23

Blümcke I, Aronica E, Becker A, et al. Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification. *Nature Reviews Neurology* 2016;**12**:732–40. doi:10.1038/nrneurol.2016.173

24

Chhabda S, Carney O, D'Arco F, et al. The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. *Quantitative Imaging in Medicine and Surgery* 2016;**6**:486–9. doi:10.21037/qims.2016.10.01

25

Schwartzentruber J, Korshunov A, Liu X-Y, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 2012;**482**:226–31. doi:10.1038/nature10833

26

Sturm D, Witt H, Hovestadt V, et al. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. *Cancer Cell* 2012;**22**:425–37. doi:10.1016/j.ccr.2012.08.024

27

Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. *Science* 2013;**340**:857–61. doi:10.1126/science.1232245

28

Bender S, Tang Y, Lindroth AM, et al. Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. *Cancer Cell* 2013;**24**:660–72. doi:10.1016/j.ccr.2013.10.006

29

Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. *Nature Medicine* 2014;**20**:1394–6. doi:10.1038/nm.3716

30

Pathania M, De Jay N, Maestro N, et al. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. *Cancer Cell* 2017;**32**:684–700.e9. doi:10.1016/j.ccell.2017.09.014

31

Larson JD, Kasper LH, Paugh BS, et al. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. *Cancer Cell* Published Online First: December 2018. doi:10.1016/j.ccell.2018.11.015

32

Martinez-Barbera JP, Andoniadou CL. Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. *STEM CELLS* 2016;**34**:268–76. doi:10.1002/stem.2267

33

Gump JM, Donson AM, Birks DK, et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. *Acta Neuropathologica Communications* 2015;**3**. doi:10.1186/s40478-015-0211-5

34

Martinez-Barbera JP, Buslei R. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models. *Journal of Pediatric Endocrinology and Metabolism* 2015;**28**. doi:10.1515/jpem-2014-0442

35

Goschzik T, Gessi M, Dreschmann V, et al. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. *Journal of Neuropathology & Experimental Neurology* Published Online First: 9 January 2017. doi:10.1093/jnen/nlw116

36

Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma. *Seminars in Cancer Biology* 2011;**21**:267–75. doi:10.1016/j.semcancer.2011.09.005

37

Beierle EA. MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK). *Frontiers in bioscience (Elite edition)*;**3**.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>

38

Bell E, Chen L, Liu T, et al. MYCN oncoprotein targets and their therapeutic potential. *Cancer Letters* 2010;**293**:144–57. doi:10.1016/j.canlet.2010.01.015

39

Berry T, Luther W, Bhatnagar N, et al. The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. *Cancer Cell* 2012;**22**:117-30. doi:10.1016/j.ccr.2012.06.001

40

Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. *Nature Reviews Cancer* 2003;**3**:203-16. doi:10.1038/nrc1014

41

Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. *Nature Reviews Clinical Oncology* 2014;**11**:704-13. doi:10.1038/nrclinonc.2014.168

42

Garrett M, Brodeur, Robert C, Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage. *Science* 1984;**224**:1121-4. <http://www.jstor.org/stable/1692440>

43

Burkhart CA, Cheng AJ, Madafiglio J, et al. Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. *JNCI Journal of the National Cancer Institute* 2003;**95**:1394-403. doi:10.1093/jnci/djg045

44

Chen L, Iraci N, Gherardi S, et al. p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. *Cancer Research* 2010;**70**:1377-88. doi:10.1158/0008-5472.CAN-09-2598

45

Cossu I, Bottoni G, Loi M, et al. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Biomaterials 2015;**68**:89–99. doi:10.1016/j.biomaterials.2015.07.054

46

Evans AE, Baum E, Chard R. Do infants with stage IV-S neuroblastoma need treatment? Archives of Disease in Childhood 1981;**56**:271–4. doi:10.1136/adc.56.4.271

47

Guglielmi L, Cinnella C, Nardella M, et al. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death & Disease 2014;**5**:e1081–e1081. doi:10.1038/cddis.2014.42

48

Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine 2013;**3**:a014415–a014415. doi:10.1101/cshperspect.a014415

49

Huber K, Kalcheim C, Unsicker K. The development of the chromaffin cell lineage from the neural crest. Autonomic Neuroscience 2009;**151**:10–6. doi:10.1016/j.autneu.2009.07.020

50

Liu Z, Thiele CJ. ALK and MYCN: When Two Oncogenes Are Better than One. Cancer Cell 2012;**21**:325–6. doi:10.1016/j.ccr.2012.03.004

51

Marabelle A, Sapin V, Rousseau R, et al. Hypercalcemia and 13-<sup>132</sup>I-<sup>125</sup>I-retinoic acid in post-consolidation therapy of neuroblastoma. Pediatric Blood & Cancer 2009;**52**:280–3. doi:10.1002/pbc.21768

52



Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-  
-Retinoic Acid. *New England Journal of Medicine* 1999;**341**:1165-73.  
doi:10.1056/NEJM199910143411601

53

Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature* 2008;**455**:930-5. doi:10.1038/nature07261

54

Pastorino F, Marimpietri D, Brignole C, et al. Ligand-Targeted Liposomal Therapies of Neuroblastoma. *Current Medicinal Chemistry* 2007;**14**:3070-8.  
doi:10.2174/092986707782793916

55

Qiao J, Paul P, Lee S, et al. PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. *Biochemical and Biophysical Research Communications* 2012;**424**:421-6. doi:10.1016/j.bbrc.2012.06.125

56

Reynolds CP, Matthay KK, Villablanca JG, et al. Retinoid therapy of high-risk neuroblastoma. *Cancer Letters* 2003;**197**:185-92. doi:10.1016/S0304-3835(03)00108-3

57

Schwab M. MYCN in neuronal tumours. *Cancer Letters* 2004;**204**:179-87.  
doi:10.1016/S0304-3835(03)00454-3

58

Sidell N. Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro. *JNCI: Journal of the National Cancer Institute Published Online First*: 1982. doi:10.1093/jnci/68.4.589

59

Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer Genome Landscapes. *Science* 2013;**339**:1546–58. doi:10.1126/science.1235122

60

Wright JH. NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED. *The Journal of Experimental Medicine* 1910;**12**. doi:10.1084/jem.12.4.556

61

Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. PHOX2B Is Associated with Neuroblastoma Cell Differentiation. *Cancer Biotherapy & Radiopharmaceuticals*;**31**:44–51. doi:10.1089/cbr.2015.1952

62

Zhu S, Lee J-S, Guo F, et al. Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis. *Cancer Cell* 2012;**21**:362–73. doi:10.1016/j.ccr.2012.02.010

63

Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. *British Journal of Haematology* 2011;**154**:185–95. doi:10.1111/j.1365-2141.2011.08724.x

64

Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. *British Journal of Haematology* 2008;**140**:610–24. doi:10.1111/j.1365-2141.2007.06958.x

65

Wegman-Ostrosky T, Savage SA. The genomics of inherited bone marrow failure: from mechanism to the clinic. *British Journal of Haematology* 2017;**177**:526–42. doi:10.1111/bjh.14535

66

Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. *Nature Reviews Cancer* 2008;**8**:473–80. doi:10.1038/nrc2394

67

Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* 2007;**450**:903–7. doi:10.1038/nature06309

68

Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer. *Nature Reviews Clinical Oncology* 2014;**11**:693–703. doi:10.1038/nrclinonc.2014.177

69

Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine* 2016;**22**:26–36. doi:10.1038/nm.4015

70

*Nature Reviews Immunology*. 2012;**12**.<https://www.nature.com/nri/volumes/12/issues/4>

71

Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. *Cancer Cell* 2017;**31**:476–85. doi:10.1016/j.ccell.2017.03.002

72

Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. *Nature Reviews Cancer* 2003;**3**:639–49. doi:10.1038/nrc1164

73

Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. *Oncogene* 2004;**23**:4275–83. doi:10.1038/sj.onc.1207672

74

Slany RK. The molecular mechanics of mixed lineage leukemia. *Oncogene* 2016;**35**:5215–23. doi:10.1038/onc.2016.30

75

Milne TA. Mouse models of MLL leukemia: recapitulating the human disease. *Blood* 2017;**129**:2217–23. doi:10.1182/blood-2016-10-691428

76

Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. *Nature* 2017;**545**:423–31. doi:10.1038/nature22395

77

Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. *Cell Research* 2017;**27**:38–58. doi:10.1038/cr.2016.154

78

Yong CSM, Dardalhon V, Devaud C, et al. CAR T-cell therapy of solid tumors. *Immunology and Cell Biology* 2017;**95**:356–63. doi:10.1038/icb.2016.128

79

Fisher J, Abramowski P, Wisidagamage Don ND, et al. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. *Molecular Therapy* 2017;**25**:1234–47. doi:10.1016/j.ymthe.2017.03.002

80

Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. *New England Journal of Medicine* 2016;**375**:2561–9. doi:10.1056/NEJMoa1610497

81

Morsut L, Roybal KT, Xiong X, et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. *Cell* 2016;**164**:780–91. doi:10.1016/j.cell.2016.01.012

82

Rasaiyaah J, Georgiadis C, Preece R, et al. TCR $\alpha\beta$ /CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. *JCI Insight* 2018;**3**. doi:10.1172/jci.insight.99442

83

Ghorashian S, Amrolia P, Veys P. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. *Experimental Hematology* 2018;**66**:5–16. doi:10.1016/j.exphem.2018.07.002

84

Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Science Translational Medicine* 2017;**9**. doi:10.1126/scitranslmed.aaj2013

85

Hubert CG, Rivera M, Spangler LC, et al. A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found. *Cancer Research* 2016;**76**:2465–77. doi:10.1158/0008-5472.CAN-15-2402

86

Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. *Disease Models and Mechanisms* 2008;**1**:78–82. doi:10.1242/dmm.000976

87

Phoenix TN, Patmore DM, Boop S, et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. *Cancer Cell* 2016;**29**:508–22. doi:10.1016/j.ccell.2016.03.002

88

Lu B, Green B, Farr J, et al. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. *Cancers* 2016;**8**. doi:10.3390/cancers8090082

89

Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. *Nature Reviews Neurology* 2012;**8**:340–51. doi:10.1038/nrneurol.2012.78

90

Niklison-Chirou MV, Erngren I, Engskog M, et al. TAp73 is a marker of glutamine addiction in medulloblastoma. *Genes & Development* 2017;**31**:1738–53. doi:10.1101/gad.302349.117

91

Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. *Nature Reviews Clinical Oncology* 2013;**10**:460–71. doi:10.1038/nrclinonc.2013.100

92

Kotrova M, Trka J, Kneba M, et al. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? *Molecular Diagnosis & Therapy* 2017;**21**:481–92. doi:10.1007/s40291-017-0277-9

93

O'Connor D, Enshaei A, Bartram J, et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology* 2018;**36**:34–43. doi:10.1200/JCO.2017.74.0449

94

Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. *The Lancet Oncology* 2013;**14**:199–209. doi:10.1016/S1470-2045(12)70600-9

95

Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. *The Lancet Oncology* 2014;**15**:809–18. doi:10.1016/S1470-2045(14)70243-8

96

Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *New England Journal of Medicine* 2015;**373**:1541–52. doi:10.1056/NEJMra1400972

97

O'Connor D, Enshaei A, Bartram J, et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology* 2018;**36**:34–43. doi:10.1200/JCO.2017.74.0449